

antibody comprising a specificity for an immune checkpoint molecule; optionally, wherein the anti-CD96 antibody is the sole active agent of the composition

**20.** A method of treating a CD96 mediated disease in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim **13**; optionally, wherein the disease is a viral infection or cancer.

\* \* \* \* \*